



[Handwritten signature]

Docket No.: 59752(70207)
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
David Butler et al.

Application No.: 10/575,177 ✓

Confirmation No.:

Filed: April 7, 2006

Art Unit: N/A

For: PYROVALERONE ANALOGUES AND
THERAPEUTIC USES THEREOF

Examiner: Not Yet Assigned

INFORMATION DISCLOSURE STATEMENT (IDS)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is filed before the mailing date of a first Office Action on the merits as far as is known to the undersigned (37 CFR 1.97(b)(3)).

In accordance with 37 CFR 1.98(a)(2)(ii), Applicant has not submitted copies of U.S. patents and U.S. patent applications. Applicant submits herewith copies of foreign patents and non-patent literature in accordance with 37 CFR 1.98(a)(2).

A concise explanation of relevance of the items listed on form PTO/SB/08 is in the form of an English language copy of a Search Report from a foreign patent office, issued in a counterpart application, which refers to the relevant portions of the references.


In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 04-1105, under Order No. 59752(70207). A duplicate copy of this paper is enclosed.

Dated: February 19, 2007

Respectfully submitted,

By 

Gregory B. Butler, Ph.D., Esq.

Registration No.: 34,558

EDWARDS ANGELL PALMER & DODGE
LLP

P.O. Box 55874

Boston, Massachusetts 02205

(617) 439-4444

Attorneys/Agents For Applicant



PTO/SB/08A/B (09-06)

Approved for use through 03/31/2007. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|--|---|--------------------------|------------------|------------------------|--------------|
| Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) | | Complete if Known | | | |
| | | Application Number | 10/575,177 | | |
| | | Filing Date | April 7, 2006 | | |
| | | First Named Inventor | David Butler | | |
| | | Art Unit | N/A | | |
| | | Examiner Name | Not Yet Assigned | | |
| Sheet | 1 | of | 2 | Attorney Docket Number | 59752(70207) |

| U.S. PATENT DOCUMENTS | | | | | |
|-----------------------|-----------------------|---|--------------------------------|--|---|
| Examiner Initials* | Cite No. ¹ | Document Number Number-Kind Code ² (if known) | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
| | AA* | US-2,369,611 | 02-13-1945 | Scheuing et al | |
| | AB* | US-3,314,970 | 04-18-1967 | Ernst Seeger et al. | |

| FOREIGN PATENT DOCUMENTS | | | | | | |
|--------------------------|-----------------------|--|--------------------------------|--|---|----------------|
| Examiner Initials* | Cite No. ¹ | Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (if known) | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | T ⁶ |
| | BA | GB-933,507-A1 | 08-08-1963 | Thmae GMBH Dr. | | |
| | BB | EP-0 601 249-A1 | 06-15-1994 | Tanabe Seiyaku Co. | | |
| | BC | DE-26 33 889 | 02-17-1977 | Roussel-Uclaf | | |
| | BD | EP-0 441 506-A2 | 08-14-1991 | Pfizer | | |
| | BE | CH-395 998-A | 07-31-1965 | Wander AG Dr A | | |

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

| NON PATENT LITERATURE DOCUMENTS | | | | | | |
|---------------------------------|-----------------------|--|--|--|--|----------------|
| Examiner Initials | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | | | | T ² |
| | CA | Springer D. et al., "New Designer Drug 4'-Methyl- α -Pyrrolidinohexanophenone: Studies on its Metabolism and Toxicological Detection in Urine Using Gas Chromatography-Mass Spectrometry," Journal of Chromatography B: Biomedical Sciences & Applications. Vol 789, No. 1, June 5, 2003. | | | | |
| | CB | A. Tidjane Corera et al.: "Differential Sensitivity to NaCl for Inhibitors and Substrates that recognize Mutually Exclusive Binding Sites on the Neuronal Transporter of Dopamine in Rat Striatal Membranes," Neuroscience Research, Vol. 39, 2001, pages 319-325. | | | | |
| | CC | Michaelis W. et al., "The Metabolism of Pyrovalerone Hydrochloride," Journal of Medicinal Chemistry, American Chemical Society, Washington, US, Vol. 13, No. 3, 1970, pages 497-503. | | | | |
| | CD | M. Yoshimoto et al., "A New General Method for Carbon-Carbon Condensation of Conjugated Enaminoketones at the Gamma -position," Tetrahedron Letters, No. 1, 1973, pages 39-42. | | | | |
| | CE | Straus F. et al., "Uber die Addition von Stickoxyden und von Nitrosylchlorid an delta-Dihydronaphthalin," Justus Liebigs Annalen Der Chemie, vol. 444, 1925, pages 146-164. | | | | |
| | CF | R. E. Lutz et al., "Antimalarials. alpha-Phenyl-beta-Dialkylamino Alcohols." Journal of Organic Chemistry, Vol. 12, 1947, pages 617-703. | | | | |
| | CG | Heffe, "Die Stevens-Umlagerung von Allyl-phenacyl-ammoniumsalzen." Helvetica Chimica Acta, Vol. 47, No. 5, 1964, pages 1289-1292. | | | | |
| | CH | A. C. Sayers et al., "A Study of the Role of Catecholamines in the Response to Various Central Stimulants." European Journal of Pharmacology, Vol. 23, 1973, pages 47-55. | | | | |
| | CI | C. Heron et al., "Evidence that Pure Uptake Inhibitors Including Cocaine Interact Slowly with | | | | |

| | | | |
|--------------------|--|-----------------|--|
| Examiner Signature | | Date Considered | |
|--------------------|--|-----------------|--|

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|--|---|----|---|--------------------------|------------------|
| Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i> | | | | Complete if Known | |
| | | | | Application Number | 10/575,177 |
| | | | | Filing Date | April 7, 2006 |
| | | | | First Named Inventor | David Butler |
| | | | | Art Unit | N/A |
| | | | | Examiner Name | Not Yet Assigned |
| Sheet | 2 | of | 2 | Attorney Docket Number | 59752(70207) |

| | | | |
|--|--|--|--|
| | | the Dopamine Neuronal Carrier." European Journal of Pharmacology, Vol. 264, 1994, pages 391-398. | |
|--|--|--|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

| | | | |
|-----------------------|--|--------------------|--|
| Examiner Signature | | Date Considered | |
|-----------------------|--|--------------------|--|

